SCNI
Income statement / Annual
Last year (2023), Scinai Immunotherapeutics Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Scinai Immunotherapeutics Ltd.'s net income was -$6.50 M.
See Scinai Immunotherapeutics Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.21 M
|
$5.77 M
|
$3.25 M
|
$16.01 M
|
$19.88 M
|
$19.27 M
|
$5.58 M
|
$2.44 M
|
$2.76 M
|
$1.65 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.51 M
|
$5.30 M
|
$7.63 M
|
$5.19 M
|
$2.81 M
|
$1.38 M
|
$1.40 M
|
$1.07 M
|
$871,808.00
|
$680,132.00
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$23.49 M
|
$1.00
|
-$38,239.00
|
-$185,653.00
|
-$416,061.00
|
-$726,293.00
|
-$243,564.00
|
| Operating Expenses |
$9.72 M
|
$11.06 M
|
$10.87 M
|
-$2.28 M
|
$22.69 M
|
$20.61 M
|
$6.80 M
|
$3.09 M
|
$2.90 M
|
$2.09 M
|
| Cost And Expenses |
$9.72 M
|
$11.06 M
|
$10.87 M
|
-$2.28 M
|
$22.69 M
|
$20.61 M
|
$6.80 M
|
$3.09 M
|
$2.90 M
|
$2.09 M
|
| Interest Income |
$122,683.00
|
$8.10 M
|
$928.76
|
-$9,706.00
|
$8,300.00
|
$1.35 M
|
$5,043.06
|
$14,375.00
|
$2,830.85
|
$21,194.00
|
| Interest Expense |
-$317.00
|
$5.05 M
|
-$3.15 M
|
$338,758.00
|
$4.28 M
|
$3.78 M
|
-$129.95
|
$100.00
|
$7.80
|
$1,689.00
|
| Depreciation & Amortization |
$514,000.00
|
$562,000.00
|
$471,000.00
|
$468,561.00
|
$461,688.00
|
$69,526.00
|
$123,554.00
|
$162,316.00
|
$161,615.00
|
$173,754.00
|
| EBITDA |
-$9.19 M |
-$10.50 M |
-$10.39 M |
$2.75 M |
-$22.21 M |
-$20.54 M |
-$6.67 M |
-$2.93 M |
-$2.74 M |
-$1.92 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.22 M
|
$5.27 M
|
$2.67 M
|
-$3.67 M
|
-$8.93 M
|
-$2.85 M
|
-$3.13 M
|
$704,942.00
|
$283,331.00
|
$97,015.00
|
| Income Before Tax |
-$6.50 M
|
-$5.80 M
|
-$8.21 M
|
-$1.39 M
|
-$31.62 M
|
-$23.46 M
|
-$9.93 M
|
-$2.38 M
|
-$2.62 M
|
-$1.99 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$6.50 M
|
-$5.80 M
|
-$8.21 M
|
-$1.39 M
|
-$31.62 M
|
-$23.46 M
|
-$9.93 M
|
-$2.38 M
|
-$2.62 M
|
-$1.99 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-16.64 |
-30.74 |
-58.14 |
-12.51 |
-387.21 |
-358.95 |
-197.58 |
-70.58 |
-99.22 |
-146.8 |
| EPS Diluted |
-16.64 |
-30.74 |
-58.14 |
-12.51 |
-387.21 |
-358.95 |
-197.58 |
-70.58 |
-99.22 |
-146.8 |
| Weighted Average Shares Out |
$390,656.00
|
$188,519.00
|
$141,143.00
|
$110,814.00
|
$81,662.00
|
$65,354.00
|
$50,257.00
|
$33,774.00
|
$26,380.00
|
$13,574.00
|
| Weighted Average Shares Out Diluted |
$390,656.00
|
$188,519.00
|
$141,143.00
|
$110,815.00
|
$81,662.00
|
$65,355.00
|
$50,257.00
|
$33,774.00
|
$26,381.00
|
$13,574.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
